C

CalciMedica Inc
NASDAQ:CALC

Watchlist Manager
CalciMedica Inc
NASDAQ:CALC
Watchlist
Price: 4.59 USD 0.66%
Market Cap: 66.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of CALC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CALC Relative Value
Base Case
Not Available
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.4
Industry
21.7
Forward
-2.6
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.4
Industry
16.6
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-1.9
Industry
22.5
vs History
vs Industry
24
Median 3Y
2
Median 5Y
1.3
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
55
Median 3Y
-0.5
Median 5Y
-0
Industry
13.1
Forward
-2
vs History
vs Industry
51
Median 3Y
-0.5
Median 5Y
-0.4
Industry
16.6
Forward
-2.3
vs History
vs Industry
53
Median 3Y
-0.6
Median 5Y
-0.4
Industry
15.8
vs History
vs Industry
41
Median 3Y
-0.6
Median 5Y
-0.4
Industry
19.1
vs History
vs Industry
0
Median 3Y
-15.6
Median 5Y
-7.3
Industry
1.9

Multiples Across Competitors

CALC Competitors Multiples
CalciMedica Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CalciMedica Inc
NASDAQ:CALC
65.4m USD 0 -2.8 -2.4 -2.4
US
Eli Lilly and Co
NYSE:LLY
954.7B USD 16.1 51.9 34.8 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
505.3B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
250.5B CHF 4.1 26.6 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP 4.8 29.8 108.3 158.5
CH
Novartis AG
SIX:NOVN
202.1B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
246.3B USD 3.8 12.9 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.8 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
206B USD 88.8 -70.5 326.5 818.8
US
Pfizer Inc
NYSE:PFE
146.7B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
C
CalciMedica Inc
NASDAQ:CALC
Average P/E: 23.5
Negative Multiple: -2.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.6
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -70.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
CalciMedica Inc
NASDAQ:CALC
Average EV/EBITDA: 438.1
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
326.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
CalciMedica Inc
NASDAQ:CALC
Average EV/EBIT: 1 879.9
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
818.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3